London, UK – Ipsos Healthcare, the global healthcare division of Ipsos, has added the Stroke Prevention in Atrial Fibrillation (SPAF) Monitor to its syndicated Cardiovascular Therapy Monitor Portfolio.
The SPAF Monitor, which arrives at a critical juncture in this therapy area, allows clients to understand and track SPAF treatment across the EU5, US, South Korea, Japan and Brazil. Q1 2013 data is now available and reveals current drug shares, doctors’ current and future prescribing intentions, and the attributes driving their decision-making. Ipsos Healthcare’s Cardiovascular Therapy Monitor Portfolio also covers Venous Thromboembolism (VTE), Pulmonary Arterial Hypertension (PAH) and Hypertension.
Dr Sabina Heinz, Head of Ipsos Healthcare’s Cardiovascular Therapy Monitor Portfolio, commented:
“For decades, Stroke Prevention in Atrial Fibrillation has been treated with Warfarin – which puts a considerable burden on the patient – or simply, with aspirin. Now, the SPAF treatment landscape has been transformed by the introduction of Novel Oral Anticoagulants (NOACs). Against this backdrop, our SPAF monitor will answer critical questions such as, ‘What split of drugs are doctors giving to their patients right now?’, and, more importantly, ‘What do they expect to be doing in 12 months’ time’?”
For more information on this news release please contact:
Dr Sabina Heinz
Head of Cardiovascular Therapy Monitors
+44 (0)203 059 5298
Marketing Director, Syndicated Services
+44 7818 422117
About Ipsos Healthcare’s Global Therapy Monitors
Ipsos Healthcare’s Global Therapy Monitors comprise the industry’s largest portfolio of syndicated patient chart audit data. The suite of global studies tracks usage of treatments across 20+ disease areas, including Metabolics, Oncology, Virology, Autoimmune, Cardiovascular and more. Together, they encompass 4000 physicians reporting on 200,000 patients in 35 markets worldwide. Subscribers to the Global Therapy Monitors can track product usage and maintain a comprehensive understanding of their ever-evolving markets.
About Ipsos Healthcare
Ipsos Healthcare is a global specialised practice focusing on research in the pharmaceutical, bio-tech and medical device markets. It is also a leading provider of global syndicated patient chart studies in 35 markets. Operating in over 40 countries, the team of 500 healthcare market research experts, marketers and client-side brand-builders focuses on delivering outcome-oriented research for its clients. Drawing from a broad range of qualitative and quantitative techniques, Ipsos Healthcare offers custom and syndicated research programs to evaluate the motivations, experiences, interactions and influences of stakeholders forming the multi-customer markets that increasingly drive business success in the healthcare industry.
Ipsos is an independent market research company controlled and managed by research professionals. Founded in France in 1975, Ipsos has grown into a worldwide research group with a strong presence in all key markets. In October 2011 Ipsos completed the acquisition of Synovate. The combination forms the world’s third largest market research company. With offices in 85 countries, Ipsos delivers insightful expertise across six research specializations: advertising, customer loyalty, marketing, media, public affairs research, and survey management.
Ipsos researchers assess market potential and interpret market trends. They develop and build brands. They help clients build long-term relationships with their customers. They test advertising and study audience responses to various media and they measure public opinion around the globe.
Ipsos has been listed on the Paris Stock Exchange since 1999 and generated global revenues of €1,789 billion (2.300 billion USD) in 2012.
Visit www.ipsos.com to learn more about Ipsos’ offerings and capabilities.